These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12871098)

  • 1. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families.
    Lewis DF
    Curr Med Chem; 2003 Oct; 10(19):1955-72. PubMed ID: 12871098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF; Jacobs MN; Dickins M
    Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 57 varieties: the human cytochromes P450.
    Lewis DF
    Pharmacogenomics; 2004 Apr; 5(3):305-18. PubMed ID: 15102545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism.
    Lewis DF; Dickins M
    Drug Metab Rev; 2003 Feb; 35(1):1-18. PubMed ID: 12635813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenobiotic metabolism in the zebrafish: a review of the spatiotemporal distribution, modulation and activity of Cytochrome P450 families 1 to 3.
    Saad M; Cavanaugh K; Verbueken E; Pype C; Casteleyn C; Van Ginneken C; Van Cruchten S
    J Toxicol Sci; 2016 Feb; 41(1):1-11. PubMed ID: 26763387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism.
    Lewis DF; Modi S; Dickins M
    Drug Metabol Drug Interact; 2001; 18(3-4):221-42. PubMed ID: 11791886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.
    Lewis DF; Lake BG; George SG; Dickins M; Eddershaw PJ; Tarbit MH; Beresford AP; Goldfarb PS; Guengerich FP
    Toxicology; 1999 Nov; 139(1-2):53-79. PubMed ID: 10614688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
    Lewis DF
    Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles.
    Lewis DF
    Toxicology; 2000 Apr; 144(1-3):197-203. PubMed ID: 10781888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship for human cytochrome P450 substrates and inhibitors.
    Lewis DF; Modi S; Dickins M
    Drug Metab Rev; 2002; 34(1-2):69-82. PubMed ID: 11996013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the estimation of binding affinity (deltaGbind) for human P450 substrates (based on Km and KD values).
    Lewis DF
    Curr Drug Metab; 2003 Oct; 4(5):331-40. PubMed ID: 14529365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity.
    Lewis DF; Lake BG; Dickins M
    J Enzyme Inhib Med Chem; 2007 Feb; 22(1):1-6. PubMed ID: 17373540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome p450 expression in the liver of food-producing animals.
    Ioannides C
    Curr Drug Metab; 2006 May; 7(4):335-48. PubMed ID: 16724924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions.
    Lewis DF; Ito Y
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1181-6. PubMed ID: 18721112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.
    Yap CW; Xue Y; Li ZR; Chen YZ
    Curr Top Med Chem; 2006; 6(15):1593-607. PubMed ID: 16918471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.
    Toselli F; Dodd PR; Gillam EM
    Drug Metab Rev; 2016 Aug; 48(3):379-404. PubMed ID: 27498925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.
    Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 2001 Nov; 41(11):1149-79. PubMed ID: 11697750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
    Lewis DF
    Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences.
    Lewis DF; Ito Y; Lake BG
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):679-84. PubMed ID: 20100069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of coumarin by human P450s: a molecular modelling study.
    Lewis DF; Ito Y; Lake BG
    Toxicol In Vitro; 2006 Mar; 20(2):256-64. PubMed ID: 16157466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.